538 related articles for article (PubMed ID: 27522545)
1. Expanding role of molecular chaperones in regulating α-synuclein misfolding; implications in Parkinson's disease.
Sharma SK; Priya S
Cell Mol Life Sci; 2017 Feb; 74(4):617-629. PubMed ID: 27522545
[TBL] [Abstract][Full Text] [Related]
2. Applying chaperones to protein-misfolding disorders: molecular chaperones against α-synuclein in Parkinson's disease.
Chaari A; Hoarau-Véchot J; Ladjimi M
Int J Biol Macromol; 2013 Sep; 60():196-205. PubMed ID: 23748003
[TBL] [Abstract][Full Text] [Related]
3. Molecular chaperones and Parkinson's disease.
Hu S; Tan J; Qin L; Lv L; Yan W; Zhang H; Tang B; Wang C
Neurobiol Dis; 2021 Dec; 160():105527. PubMed ID: 34626793
[TBL] [Abstract][Full Text] [Related]
4. Chaperone proteostasis in Parkinson's disease: stabilization of the Hsp70/alpha-synuclein complex by Hip.
Roodveldt C; Bertoncini CW; Andersson A; van der Goot AT; Hsu ST; Fernández-Montesinos R; de Jong J; van Ham TJ; Nollen EA; Pozo D; Christodoulou J; Dobson CM
EMBO J; 2009 Dec; 28(23):3758-70. PubMed ID: 19875982
[TBL] [Abstract][Full Text] [Related]
5. Involvement of molecular chaperone in protein-misfolding brain diseases.
Wankhede NL; Kale MB; Upaganlawar AB; Taksande BG; Umekar MJ; Behl T; Abdellatif AAH; Bhaskaran PM; Dachani SR; Sehgal A; Singh S; Sharma N; Makeen HA; Albratty M; Dailah HG; Bhatia S; Al-Harrasi A; Bungau S
Biomed Pharmacother; 2022 Mar; 147():112647. PubMed ID: 35149361
[TBL] [Abstract][Full Text] [Related]
6. Protein Misfolding Diseases.
Hartl FU
Annu Rev Biochem; 2017 Jun; 86():21-26. PubMed ID: 28441058
[TBL] [Abstract][Full Text] [Related]
7. Human Hsp70 Disaggregase Reverses Parkinson's-Linked α-Synuclein Amyloid Fibrils.
Gao X; Carroni M; Nussbaum-Krammer C; Mogk A; Nillegoda NB; Szlachcic A; Guilbride DL; Saibil HR; Mayer MP; Bukau B
Mol Cell; 2015 Sep; 59(5):781-93. PubMed ID: 26300264
[TBL] [Abstract][Full Text] [Related]
8. Molecular chaperones and protein folding as therapeutic targets in Parkinson's disease and other synucleinopathies.
Ebrahimi-Fakhari D; Saidi LJ; Wahlster L
Acta Neuropathol Commun; 2013 Dec; 1(1):79. PubMed ID: 24314025
[TBL] [Abstract][Full Text] [Related]
9. Small molecule-mediated stabilization of vesicle-associated helical α-synuclein inhibits pathogenic misfolding and aggregation.
Fonseca-Ornelas L; Eisbach SE; Paulat M; Giller K; Fernández CO; Outeiro TF; Becker S; Zweckstetter M
Nat Commun; 2014 Dec; 5():5857. PubMed ID: 25524885
[TBL] [Abstract][Full Text] [Related]
10. Protein Misfolding and Aggregation: The Relatedness between Parkinson's Disease and Hepatic Endoplasmic Reticulum Storage Disorders.
Padilla-Godínez FJ; Ramos-Acevedo R; Martínez-Becerril HA; Bernal-Conde LD; Garrido-Figueroa JF; Hiriart M; Hernández-López A; Argüero-Sánchez R; Callea F; Guerra-Crespo M
Int J Mol Sci; 2021 Nov; 22(22):. PubMed ID: 34830348
[TBL] [Abstract][Full Text] [Related]
11. Reversing deleterious protein aggregation with re-engineered protein disaggregases.
Jackrel ME; Shorter J
Cell Cycle; 2014; 13(9):1379-83. PubMed ID: 24694655
[TBL] [Abstract][Full Text] [Related]
12. Molecular dissection of amyloid disaggregation by human HSP70.
Wentink AS; Nillegoda NB; Feufel J; Ubartaitė G; Schneider CP; De Los Rios P; Hennig J; Barducci A; Bukau B
Nature; 2020 Nov; 587(7834):483-488. PubMed ID: 33177717
[TBL] [Abstract][Full Text] [Related]
13. Potentiated Hsp104 variants antagonize diverse proteotoxic misfolding events.
Jackrel ME; DeSantis ME; Martinez BA; Castellano LM; Stewart RM; Caldwell KA; Caldwell GA; Shorter J
Cell; 2014 Jan; 156(1-2):170-82. PubMed ID: 24439375
[TBL] [Abstract][Full Text] [Related]
14. Protein Misfolding Diseases and Therapeutic Approaches.
Yadav K; Yadav A; Vashistha P; Pandey VP; Dwivedi UN
Curr Protein Pept Sci; 2019; 20(12):1226-1245. PubMed ID: 31187709
[TBL] [Abstract][Full Text] [Related]
15. Molecular chaperone dysfunction in neurodegenerative diseases and effects of curcumin.
Maiti P; Manna J; Veleri S; Frautschy S
Biomed Res Int; 2014; 2014():495091. PubMed ID: 25386560
[TBL] [Abstract][Full Text] [Related]
16. CSPα reduces aggregates and rescues striatal dopamine release in α-synuclein transgenic mice.
Caló L; Hidari E; Wegrzynowicz M; Dalley JW; Schneider BL; Podgajna M; Anichtchik O; Carlson E; Klenerman D; Spillantini MG
Brain; 2021 Jul; 144(6):1661-1669. PubMed ID: 33760024
[TBL] [Abstract][Full Text] [Related]
17. Pathogenesis of Parkinson's disease: emerging role of molecular chaperones.
Bandopadhyay R; de Belleroche J
Trends Mol Med; 2010 Jan; 16(1):27-36. PubMed ID: 20036196
[TBL] [Abstract][Full Text] [Related]
18. Underlying mechanisms and chemical/biochemical therapeutic approaches to ameliorate protein misfolding neurodegenerative diseases.
Hekmatimoghaddam S; Zare-Khormizi MR; Pourrajab F
Biofactors; 2017 Nov; 43(6):737-759. PubMed ID: 26899445
[TBL] [Abstract][Full Text] [Related]
19. Amyloid Oligomers: A Joint Experimental/Computational Perspective on Alzheimer's Disease, Parkinson's Disease, Type II Diabetes, and Amyotrophic Lateral Sclerosis.
Nguyen PH; Ramamoorthy A; Sahoo BR; Zheng J; Faller P; Straub JE; Dominguez L; Shea JE; Dokholyan NV; De Simone A; Ma B; Nussinov R; Najafi S; Ngo ST; Loquet A; Chiricotto M; Ganguly P; McCarty J; Li MS; Hall C; Wang Y; Miller Y; Melchionna S; Habenstein B; Timr S; Chen J; Hnath B; Strodel B; Kayed R; Lesné S; Wei G; Sterpone F; Doig AJ; Derreumaux P
Chem Rev; 2021 Feb; 121(4):2545-2647. PubMed ID: 33543942
[TBL] [Abstract][Full Text] [Related]
20. Insights into the Molecular Mechanisms of Alzheimer's and Parkinson's Diseases with Molecular Simulations: Understanding the Roles of Artificial and Pathological Missense Mutations in Intrinsically Disordered Proteins Related to Pathology.
Coskuner-Weber O; Uversky VN
Int J Mol Sci; 2018 Jan; 19(2):. PubMed ID: 29364151
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
